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We observed a sudden and rapid increase in rare invasive 
pneumococcal disease serotype 7C, from an annual av-
erage of 3 cases during 2000–01 through 2015–16 to 29 
cases in 2016–17. The increase was caused almost entirely 
by clonal expansion of sequence type 177, previously as-
sociated with vaccine serotype 19F.
The bacterium Streptococcus pneumoniae is a major glob-al cause of meningitis, septicemia, and pneumonia and 
is associated with high rates of illness and death. In Septem-
ber 2006, the childhood immunization program in the United 
Kingdom introduced PCV7, a pneumococcal conjugate vac-
cine against the 7 most common serotypes causing invasive 
pneumococcal disease (IPD) in children; a 13-valent PCV 
replaced it in April 2010 (1). Both vaccines have been as-
sociated with rapid and widespread declines in IPD across 
all age groups and, despite an increase in other disease from 
non-PCV serotypes, overall IPD rates have dropped by 56% 
and have remained lower than prevaccine rates (1).
In England and Wales, Public Health England (PHE) 
conducts enhanced national surveillance for IPD (1). Na-
tional Health Service laboratories routinely report clini-
cally significant infections to PHE and submit invasive 
isolates to the PHE National Reference Laboratory for se-
rotyping (2). We observed an unusual increase in invasive 
isolates serotyped as 7C early in 2017 that continued into 
the 2017–18 epidemiologic year. We analyzed the epide-
miology, clinical characteristics, genetic epidemiology, 
and outcomes of serotype 7C IPD since 2000–01 in Eng-
land and Wales.
The Study
We performed whole-genome sequencing (WGS) on 44 of 
66 invasive 7C isolates collected during July 2005–June 
2017, as well as 37 of 42 isolates collected during July 
2017–January 31, 2018. We used previously published 
methods for WGS analysis (3,4). We used Bowtie version 
2 (5) to map WGS reads to sequences for 1,689 antimicro-
bial-resistant genes in the ARG-ANNOT database (6). We 
used PBP typing to predict β-lactam resistance (7). Using 
MEGA7 (8), we drew a neighbor-joining tree (9) based on 
single-nucleotide polymorphism (SNP) alignments, as pre-
viously described (10). We included PHE data available on 
the European Nucleotide Archive (https://www.ebi.ac.uk/
ena) (online Technical Appendix Table, https://wwwnc.
cdc.gov/EID/article/24/10/18-0114-Techapp1.pdf) and 
used a non–sequence type (ST) 177 serotype 19F (Taiwan 
19F-14; GenBank accession no. NC_012469.1) as a refer-
ence sequence. We did not identify and remove recombi-
nation events in the WGS alignment before constructing 
the phylogeny. Data on antimicrobial drug susceptibility 
testing performed according to British Society for Antimi-
crobial Chemotherapy guidelines (11) were available on a 
subset of isolates.
From epidemiologic year 2000–01 through 2015–16, 
a total of 84,305 laboratory-confirmed IPD episodes oc-
curred in England and Wales, including 51 serotype 7C 
IPD cases; an annual average of 3 cases (range 1–6) were 
confirmed. In 2016–17, a total of 29 cases were confirmed, 
compared to 5, 4, and 4 in the previous 3 years (2013–14, 
2014–15, and 2015–16, respectively); an additional 42 cas-
es were confirmed during the first 7 months of the 2017–18 
epidemiologic year (Figure 1, panel A). We found no evi-
dence of geographic or temporal clustering of cases. Cases 
were diagnosed across all age groups and especially in 
those >65 years of age (84/122, 68.9%), including 38 cases 
in the 65–79 age group and 46 cases in persons >80 years 
of age. Of the 80 cases (93.8%) diagnosed from 2000–01 
through 2016–17, a total of 75 included bacteremia and 5 
meningitis (in patients ages 1 month, 5 months, 6 months, 
30 years, and 48 years). 
All isolates were cultured from blood or cerebrospinal 
fluid. Case-fatality ratio (CFR) was 25% (20/80) and in-
creased with age: 12.5% (1/8) in children <15 years of age, 
0 in the 15–44-year age group, 23% (3/13) in the 45–64-
year age group, 25% (6/24) in the 65–79-year age group, 
and 37% (10/27) in the >80-year age group. CFR in the old-
est 2 age groups was similar to the CFR for other serotypes 
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in those age groups (23% for the 65–79-year age group and 
40% for the >80-year age group).
The first serotype 7C isolate associated with ST177 ap-
peared in 2012–13 and again in 2014–15, followed by all 
4 cases in 2015–16 and 27/29 cases in 2016–17 (Figure 1, 
panel B). During July 2017–January 2018, a total of 35/37 
sequenced 7C isolates were associated with ST177. A re-
view of available PHE MLST data showed that ST177 was 
also associated with serotypes 19F (MLST derived for 25 
isolates during 2002–2015) and 24F (MLST derived for 13 
isolates during 2014–15).
We generated the neighbor-joining tree (Figure 2) fol-
lowing SNP analyses on 59 isolates, using MEGA7 using 
isolate Taiwan 19F-14. The tree shows that 7C-ST177 iso-
lates had a more recent common ancestor with serotypes 
19F and 24F belonging to ST177 than with non-ST177 7C 
isolates (except the single isolate belonging to ST11386, 
a single-locus variant [SLV] of ST177). The 7C-ST177 
1920 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 10, October 2018
Figure 1. Cases of invasive 
pneumococcal disease (IPD) 
caused by serotype 7C between 
epidemiologic years 2000–01 
and 2016–17 and an additional 
42 cases reported July 1, 2017, 
through January 31, 2018, by 
(A) age group and (B) MLST 
sequence type, England and 
Wales. Surveillance is not 
complete for the 2017–18 
epidemiologic year; figure shows 
only cases for the 7 months 
indicated. NA indicates missing 
sequence data.
Rapid Spread of Pneumococcal Serotype 7C
isolates were closely related, with <100 SNPs between 
them. We found >6,000 SNPs separating the 7C-ST177 
and the non-ST177 serotype 7C (except 1 SLV of ST177 
with <100 SNP distance from the ST177 isolates).
We did not detect any antimicrobial drug resistance 
determinants or PBP types suggesting β-lactam nonsus-
ceptibility in the genomes of any ST177 7C isolates. MIC 
data were available on 13 serotype 7C isolates but only 2 
were ST177; both were fully susceptible to all antimicro-
bial drugs tested.
Conclusions
In England and Wales, the recent increase in IPD due to 
the nonvaccine serotype 7C was associated with clonal 
expansion of ST177. Previously, this serotype was associ-
ated with vaccine serotype 19F, although we also observed 
serotype 24F isolates with this ST in later years. Nearly 
all the increase occurred in older adults, with no evidence 
of change in clinical presentation or CFR when compared 
with the other serotypes causing IPD in the same age 
groups. The age-related CFRs observed in our cohort are 
consistent with those from other industrialized countries 
with established PCV programs (12).
Additional WGS data from historical serotypes 19F 
and 24F isolates may help determine whether this 7C-
ST177 arose from capsular switching, which appears likely 
given the rapid expansion of this clone. It is also possible 
that the increase in serotype 24F IPD after PCV13 replaced 
PCV7 may be attributable to ST177 (1), although we did 
not investigate this in our study. IPD cases due to serotype 
24F have increased in children (from 3 to 28 cases), adults 
(from 7 to 71 cases), and older adults (from 14 to 84 cases) 
since PCV13 implementation (1).
ST177 has been associated with serotype 19F, with 
39/42 isolates submitted to the PubMLST isolates database 
associated with this serotype (https://pubmlst.org/spneu-
moniae/). In England and Wales, ST177 was represented 
exclusively by serotype 19F in elderly patients before PCV7 
introduction (13). Because serotypes 19F and 24F are com-
mon causes of IPD, we were unable to sequence all inva-
sive isolates. The clonal expansion of 7C-ST177 could be 
a consequence of natural fluctuation of nonvaccine sero-
types caused by negative frequency selection (14). Although 
ST177 is the ST of the globally disseminated Portugal 19F-
21 Pneumococcal Molecular Epidemiology Network clone 
that is multidrug resistant (15), we did not identify resistance 
determinants in any of the 7C-ST177 isolates we studied.
In summary, serotype 7C remains a rare cause of 
IPD in England and Wales but is linked to a sudden, rapid 
increase in cases of IPD because of clonal expansion of 
ST177, previously associated with vaccine serotype 19F. 
We encourage other countries to monitor pneumococcal 
surveillance programs for evidence of similar increases.
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Figure 2. Neighbor-joining tree following single-nucleotide 
polymorphism analyses on 59 pneumococcal isolates collected in 
England and Wales during July 2005–June 2017. The percentage 
of replicate trees in which the associated taxa clustered together 
in the bootstrap test (1,000 replicates) is shown next to the branch 
junctions. All positions with <90% site coverage were eliminated. 
Missing data and ambiguous bases were allowed at any position. 
There were a total of 20,359 variant positions in the final dataset. 
Red nodes represent ST177 isolates; green node, an isolate 
with SLV of ST177; black nodes, non-ST177 isolates. Squares 
represent 7C serotype; triangles, 24F serotype; and circles 19F 
serotype. The open circle represents the Taiwan 19F-14 reference 
sequence (GenBank accession no. NC_012469.1). Scale bar 
shows the number of nucleotide substitutions represented by 
branch length. ST, sequence type.
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Technical Appendix Table. Isolate designations and European Nucleotide Archive (ENA) accession numbers for whole-genome 
sequence data used in study of invasive pneumococcal disease serotype 7C  
Sample no. ENA accession no.  Serotype Sequence type 
PHESP000001 ERS2029289 24F 177 
PHESPD0753 ERS1194051 24F 177 
PHESPD0753 ERS1194051 24F 177 
PHESPV0348 ERS1194516 24F 177 
PHESPV0718 ERS1194886 24F 177 
PHESPV0725 ERS1194893 24F 177 
PHESPV0803 ERS1194971 24F 177 
PHESPV1151 ERS1195319 24F 177 
PHESPV1385 ERS1195551 24F 177 
PHESPV1386 ERS1195552 24F 177 
PHESPV1528 ERS1195692 24F 177 
PHESPV1737 ERS1195901 24F 177 
PHESPV1747 ERS1195911 24F 177 
PHESPD0806 ERS1194104 19F 177 
PHESPV1262 ERS1195430 19F 177 
PHESP000002 ERS2029290 7C 177 
PHESP000003 ERS2029291 7C 177 
PHESP000004 ERS2029292 7C 177 
PHESP000005 ERS2029293 7C 177 
PHESP000006 ERS2029294 7C 13333 
PHESP000007 ERS2029295 7C 177 
PHESP000008 ERS2029296 7C 177 
PHESP000009 ERS2029297 7C 177 
PHESP000010 ERS2029298 7C 177 
PHESP000011 ERS2029299 7C 1201 
PHESP000012 ERS2029300 7C 177 
PHESP000013 ERS2029301 7C 177 
PHESP000014 ERS2029302 7C 177 
PHESP000015 ERS2029303 7C 177 
PHESP000016 ERS2029304 7C 177 
PHESP000017 ERS2029305 7C 177 
PHESP000018 ERS2029306 7C 177 
PHESP000019 ERS2029307 7C 177 
PHESP000020 ERS2029308 7C 177 
PHESP000021 ERS2029309 7C 177 
PHESP000022 ERS2029310 7C 177 
PHESP000023 ERS2029311 7C 177 
PHESP000024 ERS2029312 7C 177 
PHESP000025 ERS2029313 7C 177 
PHESP000026 ERS2029314 7C 177 
PHESP000027 ERS2029315 7C 177 
PHESP000028 ERS2029316 7C 177 
PHESP000029 ERS2029317 7C 177 
PHESP000030 ERS2029318 7C 177 
PHESP000031 ERS2029319 7C 177 
PHESP000032 ERS2029320 7C 177 
PHESP000033 ERS2029321 7C 177 
PHESPD0208 ERS1193506 7C 4205 
PHESPD0276 ERS1193574 7C 1201 
PHESPD0320 ERS1193618 7C 1797 
 Page 2 of 2 
Sample no. ENA accession no.  Serotype Sequence type 
PHESPD0350 ERS1193648 7C 1491 
PHESPV0498 ERS1194666 7C 1201 
PHESPV0975 ERS1195143 7C 1491 
PHESPV0993 ERS1195161 7C 11386 
PHESPV1016 ERS1195184 7C 1201 
PHESPV1052 ERS1195220 7C 177 
PHESPV1594 ERS1195758 7C 177 
PHESPV1945 ERS1196109 7C 1201 
PHESPV2010 ERS1196174 7C 1201 
PHESPV2043 ERS1196207 7C 673 
 
